ArticleCancer immunology, immunotherapy : CII2026
Real-world treatment patterns and early outcomes in advanced intrahepatic cholangiocarcinoma: a descriptive case series.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis, with 70-80% of patients presenting advanced/metastatic disease. Conventional first-line chemotherapies have limitations, and targeted-immunotherapy combinations need real-world validation. This retrospective, single-center case series enrolled 12 advanced ICC patients to describe the real-world clinical characteristics, treatment patterns which including lenvatinib-based targeted-immunotherapy with or without Transarterial Interventional Therapies (TAIT) and conventional chemotherapy, as well as early efficacy and safety outcomes; and to generate preliminary hypotheses for subsequent prospective studies, without any intention to compare the efficacy of different regimens. Among the 12 patients, objective response rate was 33.3%, and disease control rate 83.33%. Nine received lenvatinib + PD-1/PD-L1 inhibitors (targeted-immunotherapy group), and 3 received systemic chemotherapy. Among patients receiving lenvatinib + PD-1/PD-L1 inhibitors, 22.22% experienced grade ≥ 3 treatment-related adverse events (TRAEs) with a median treatment duration of 9.0 months; among patients receiving conventional chemotherapy, 66.7% experienced grade ≥ 3 TRAEs with a median treatment duration of 19.0 months. Early TAIT (≤ 2 weeks) was associated with higher tumor reduction (mean 30.52 vs. 7.69% for non-early), which may help alleviate tumor-related symptoms in patients with high initial tumor burden. Baseline CA19-9 and albumin/globulin ratio showed exploratory potential associations with treatment efficacy without formal statistical analysis; larger initial diameter correlated with better response. This study describes that lenvatinib + Immune Checkpoint Inhibitors (ICIs) combined with early TAIT may be a feasible multimodal strategy used in real-world practice for advanced ICC, with preliminary observations of feasibility. Limitations include small single-center sample and short follow-up. The high heterogeneity of treatment regimens may also limit the comparability of efficacy and safety. Larger prospective studies are needed.
Indexed as
Identifiers
42417858What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.